Age-related differences in the occurrence, severity, and distress of symptoms in older patients at the initiation of chemotherapy
Background Evaluate for differences in occurrence, severity, and distress ratings for 32 symptoms between younger older adults (YOA, < 70 years) and older adults (OA, ≥ 70 years) at initiation of chemotherapy. Methods Patients (n = 125) were recruited prior to the initiation of chemotherapy and completed the Memorial Symptom Assessment Scale. Differences in occurrence, severity, and distress ratings were evaluated using Independent sample t-tests and Chi-square or Fisher’s exact tests. Results On average, the older patients reported ten concurrent symptoms that equates with a moderate symptom burden. Symptoms with the highest occurrence rates were not always the most severe and/or the most distressing. Few age-related differences were found in patients’ symptom experiences. When age-related differences were identified, OA reported lower occurrence, severity, and distress ratings. Nine of the ten symptoms with highest occurrence rates were common for both age groups. For severity and distress, only half of the symptoms were common. In terms of severity and distress, all of the top ten ranked symptoms were in the moderate to severe range. Conclusions Both YOA and OA reported a moderate symptom burden and severity and distress scores in the moderate to severe range. The symptoms with the highest occurrence rates were not always the most severe/or the most distressing. Our findings suggest that different dimensions of the symptom experience (i.e., occurrence, severity, and distress) warrant evaluation in older oncology patients..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC geriatrics - 23(2023), 1 vom: 09. Aug. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Johannessen, Marlen Sunde [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
BKL: | |
---|---|
Themen: |
Anmerkungen: |
© BioMed Central Ltd., part of Springer Nature 2023 |
---|
doi: |
10.1186/s12877-023-04198-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2144927804 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2144927804 | ||
003 | DE-627 | ||
005 | 20240322072748.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240118s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12877-023-04198-1 |2 doi | |
035 | |a (DE-627)OLC2144927804 | ||
035 | |a (DE-He213)s12877-023-04198-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Johannessen, Marlen Sunde |e verfasserin |4 aut | |
245 | 1 | 0 | |a Age-related differences in the occurrence, severity, and distress of symptoms in older patients at the initiation of chemotherapy |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © BioMed Central Ltd., part of Springer Nature 2023 | ||
520 | |a Background Evaluate for differences in occurrence, severity, and distress ratings for 32 symptoms between younger older adults (YOA, < 70 years) and older adults (OA, ≥ 70 years) at initiation of chemotherapy. Methods Patients (n = 125) were recruited prior to the initiation of chemotherapy and completed the Memorial Symptom Assessment Scale. Differences in occurrence, severity, and distress ratings were evaluated using Independent sample t-tests and Chi-square or Fisher’s exact tests. Results On average, the older patients reported ten concurrent symptoms that equates with a moderate symptom burden. Symptoms with the highest occurrence rates were not always the most severe and/or the most distressing. Few age-related differences were found in patients’ symptom experiences. When age-related differences were identified, OA reported lower occurrence, severity, and distress ratings. Nine of the ten symptoms with highest occurrence rates were common for both age groups. For severity and distress, only half of the symptoms were common. In terms of severity and distress, all of the top ten ranked symptoms were in the moderate to severe range. Conclusions Both YOA and OA reported a moderate symptom burden and severity and distress scores in the moderate to severe range. The symptoms with the highest occurrence rates were not always the most severe/or the most distressing. Our findings suggest that different dimensions of the symptom experience (i.e., occurrence, severity, and distress) warrant evaluation in older oncology patients. | ||
650 | 4 | |a Cancer | |
650 | 4 | |a Chemotherapy | |
650 | 4 | |a Older adults | |
650 | 4 | |a Symptoms | |
650 | 4 | |a Symptom assessment | |
700 | 1 | |a Miaskowski, Christine |4 aut | |
700 | 1 | |a Kleven, Anne Grethe |4 aut | |
700 | 1 | |a Ritchie, Christine Seel |4 aut | |
700 | 1 | |a Paul, Steven M. |4 aut | |
700 | 1 | |a Grov, Ellen Karine |4 aut | |
700 | 1 | |a Hareide, Martine |4 aut | |
700 | 1 | |a Gaudernack, Henrik |4 aut | |
700 | 1 | |a Utne, Inger |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC geriatrics |d BioMed Central, 2001 |g 23(2023), 1 vom: 09. Aug. |h Online-Ressource |w (DE-627)335488994 |w (DE-600)2059865-8 |w (DE-576)107015080 |x 1471-2318 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:09 |g month:08 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12877-023-04198-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_375 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 44.00 |j Medizin: Allgemeines |j Medizin: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 09 |c 08 |